Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs (Pharmacy Benefit Managers), a national health plan and two regional health plans – thereby expanding coverage by up to 33 million lives. ZTlido (zee-tee-lie-doh) is indicated for relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.
Kellogg Expands Partnership With Sodexo For Plant-Based Burgers
Kellogg Company’s (NYSE:K) Away From Home is expanding its existing partnership with Sodexo SA (OTC:SDXAY) for three years to deliver a…
